Reinreude Tag Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts and corns.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. An optional step includes soaking the wart in warm water for approximately 5 minutes to enhance the effectiveness of the application. After washing, the area must be dried completely.

If necessary, the medicated plaster can be cut to appropriately fit the size of the wart. The plaster should then be applied directly to the wart. This application should be repeated every 48 hours as needed, with a maximum treatment duration of up to 12 weeks.

Contraindications

The product is contraindicated for use on irritated, infected, or reddened skin, as well as on genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. Application on mucous membranes is also prohibited.

Additionally, contact with the eyes or face should be avoided. In the event of accidental exposure to the eyes, it is imperative to rinse thoroughly with water.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is ingested.

It is imperative to avoid application on irritated, infected, or reddened skin. The product should not be used on genital warts, facial warts, moles, birthmarks, or any warts with hair growing from them. Additionally, application on mucous membranes is contraindicated.

Patients should be instructed to discontinue use if discomfort persists, and they should be monitored for any adverse reactions following application.

Side Effects

For external use only. Patients should discontinue use if discomfort persists. It is advised that individuals with diabetes or poor blood circulation consult a doctor prior to use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Reinreude Tag Wart Remover (salicylic acid 40% tag wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no specific information regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. The potential risks and benefits should be carefully evaluated, and alternative treatments may be considered in consultation with the patient. Women of childbearing potential should be advised to discuss their pregnancy status and any plans for pregnancy with their healthcare provider prior to initiating treatment.

Lactation

There is no information available regarding the use of REINREUDE TAG WART REMOVER (salicylic acid 40% tag wart remover patch) in lactating mothers or any lactation considerations. Consequently, the effects on breastfed infants and the excretion of salicylic acid in breast milk are not documented. Healthcare professionals should exercise caution and consider the lack of data when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary significantly depending on the substance involved and the individual patient’s characteristics. Symptoms may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate assessment of the patient's condition is crucial. Recommended actions include:

1. Assessment: Conduct a thorough evaluation of the patient's vital signs and clinical status.

2. Supportive Care: Initiate supportive measures as necessary, including airway management, oxygen supplementation, and intravenous fluids.

3. Decontamination: If appropriate and within a reasonable timeframe, consider gastrointestinal decontamination methods such as activated charcoal, provided the patient is alert and able to protect their airway.

4. Specific Antidotes: If a specific antidote is available for the substance involved, it should be administered according to established protocols.

Healthcare professionals are encouraged to consult local poison control centers or toxicology experts for guidance on management strategies tailored to the specific circumstances of the overdose. Continuous monitoring and supportive care are paramount until the patient stabilizes or further interventions are deemed necessary.

Documentation of the incident, including the substance involved, estimated dose, time of ingestion, and any interventions performed, is critical for ongoing patient management and future reference.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to inform patients that the product should not be applied to irritated, infected, or reddened skin, as well as to genital warts, warts on the face, moles, birthmarks, or warts with hair growing from them, and mucous membranes.

Patients should be counseled to monitor for any persistent discomfort following the use of the product and to report this to their healthcare provider. Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes or face. In the event that the product comes into contact with the eyes, patients should be instructed to rinse thoroughly with water.

Furthermore, patients with diabetes or poor blood circulation should be advised to consult their healthcare provider before using the product to ensure safety and appropriateness of use.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within the temperature range of 59°F to 86°F (15°C to 30°C) to maintain its efficacy and integrity. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable environment to prevent degradation. Special handling requirements should be observed to ensure the product remains within the specified temperature range throughout its storage and handling processes.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Reinreude Tag Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)